Patents Assigned to Medizinische Hochschule Hannover
-
Patent number: 11185539Abstract: The present invention relates to an inhibitor of miR-671-5p for use in a method of preventing or treating fibrosis. Further, the present invention encompasses a kit comprising said inhibitor of miR-671-5p. The present invention also relates to an in vitro method for identifying a compound for preventing or treating fibrosis.Type: GrantFiled: January 29, 2018Date of Patent: November 30, 2021Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER (MHH)Inventors: Thomas Thum, Katharina Schimmel, Quoc-Tuan Do, Philippe Bernard
-
Patent number: 11186838Abstract: The present invention relates to a compound inhibiting the expression and/or the activity of maternally expressed 3 (Meg3) for use in treating or preventing cardiac remodelling.Type: GrantFiled: April 26, 2017Date of Patent: November 30, 2021Assignee: MEDIZINISCHE HOCHSCHULE HANNOVERInventors: Thomas Thum, Maria-Teresa Piccoli, Janika Viereck, Shashi Kumar Gupta
-
Patent number: 11160831Abstract: The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.Type: GrantFiled: June 22, 2017Date of Patent: November 2, 2021Assignees: Medizinische Hochschule Hannover, Technische Universität BraunschweigInventors: Elmar Jäckel, Fatih Noyan, Michael Hust
-
Patent number: 11123358Abstract: The present invention relates to a compound for use as a medicament in the treatment or prevention of acute liver failure, which acute liver failure is induced by intoxication prior to or following administration of the compound. Accordingly, the invention relates to the compound for use in the treatment of an intoxication that without treatment is expected to result in acute liver failure or that without treatment is sufficient to induce acute liver failure. The invention also provides the compound for use in the treatment, and a corresponding method for the treatment of an intoxication sufficient to induce acute liver failure.Type: GrantFiled: May 30, 2017Date of Patent: September 21, 2021Assignee: Medizinische Hochschule HannoverInventors: Amar Sharma, Michael Ott, Tobias Cantz, Dakai Yang
-
Patent number: 11116619Abstract: A medical implant which is vacuum-packed within an air tight cover material and a medical device for making the same is provided. Also described herein is a method for making a medical implant covered by an air tight cover material, comprising the steps of a) providing the medical implant, b) providing sterile cover material in the form of at least one or at least two pieces, c) placing the medical implant within a space surrounded by the at least one or at least two pieces of the cover material, d) creating an underpressure within the space surrounded by the at least one or at least two pieces of the cover material by evacuating air from this space, and e) air tight sealing of the cover material.Type: GrantFiled: November 9, 2018Date of Patent: September 14, 2021Assignee: Medizinische Hochschule HannoverInventor: Axel Haverich
-
Patent number: 11065366Abstract: The invention relates to a method for producing a bioartificial and primarily acellular fibrin-based construct, wherein a mixture of cell-free compositions containing fibrinogen and thrombin is applied to a surface and subsequently pressurised. An additional aspect of the invention is directed to such fibrin-based bioartificial acellular constructs obtained according to the invention, with improved biomechanical properties, as well as to the use of same in the field of implantology, cartilage replacement or tissue replacement.Type: GrantFiled: July 7, 2016Date of Patent: July 20, 2021Assignee: Medizinische Hochschule HannoverInventors: Thomas Aper, Mathias Wilhelmi, Axel Haverich
-
Publication number: 20210150781Abstract: A method for processing CT imaging data includes providing CT imaging data obtained at two x-ray energy levels in a first respiratory phase, preferably in an inhalation phase, of the subject and providing second CT imaging data obtained at two x-ray energy levels in a second respiratory phase, preferably in an exhalation phase, of the subject. The method may include reconstructing first regional perfusion blood volume (PBV) imaging data from the provided first CT imaging data, reconstructing second regional PBV imaging data from the provided second CT imaging data, reconstructing first virtual non-contrast (VNC) imaging data from the provided first CT imaging data, reconstructing second VNC imaging data from the provided second CT imaging data, determining a transformation function for registering the first and second reconstructed VNC imaging data, and registering the first and second reconstructed VNC imaging data by applying the transformation function.Type: ApplicationFiled: March 28, 2019Publication date: May 20, 2021Applicant: Medizinische Hochschule HannoverInventor: Hoen-oh SHIN
-
Publication number: 20200400685Abstract: The invention relates to biomarkers for typing or classifying allograft recipients as belonging to a transplant rejection group associated with antibody-mediated rejection (ABMR). The invention also provides for the treatment of typed allograft recipients suffering from antibody-mediated rejection by administration of an appropriate therapeutic agent.Type: ApplicationFiled: December 27, 2018Publication date: December 24, 2020Applicants: VITO NV, Medizinische Hochschule Hannover, Katholieke Universiteit Leuven, Institut National de La Sante et de la Recherche Medicale (INSERM), APHP - Assistance Publique - Hôpitaux Paris, University Hospital Center of Limoges, Medizinische Hochschule HannoverInventors: Inge Mertens, Hanny Willems, Maarten Naessens, Pierre Marquet, Dany Anglicheau, Marie Essig, Wilfried Gwinner
-
Patent number: 10851359Abstract: The invention provides manipulated adenovirus, i.e. a viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. The viral particle of the invention has the advantage of having a preference or specificity for tumour cells, yielding a preferred infection of tumour cells. The viral particle is based on adenovirus, especially type C, preferably serotype 2 (Ad2), more preferably serotype 5 (Ad5), in which the native entire fiber protein, and its coding sequence, respectively, is deleted and replaced by a fusion protein providing specificity for cell surface bound polysialic acid.Type: GrantFiled: March 24, 2016Date of Patent: December 1, 2020Assignee: Medizinische Hochschule HannoverInventors: Rita Gerardy-Schahn, Florian Kuehnel, Nikolas Martin, David Schwarzer
-
Patent number: 10792854Abstract: The invention relates to a method for manufacturing a component (10) by a generative manufacturing process, wherein the component is entirely or partially produced from a liquid raw material (12), characterised in that the component is entirely or partially produced from a liquid raw material (12) that can solidify when heated, the raw material is discharged in liquid form into a manufacturing zone (1) and heated and hence solidified by a computer-controlled, targeted light spot, in that the point of incidence of a light beam (8) from a light beam source is continuously and/or gradually modified relative to the manufacturing zone (1).Type: GrantFiled: July 17, 2015Date of Patent: October 6, 2020Assignee: MEDIZINISCHE HOCHSCHULE HANNOVERInventors: Jan Stieghorst, Theodor Doll
-
Patent number: 10775389Abstract: The present invention relates to a method for identifying a subject, which has peripartum cardiomyopathy (PPCM) or which has a risk for developing PPCM, wherein the method comprises analyzing the amount and/or activity of plasminogen activator inhibitor-1 (PAI-1); and/or the genotype of the PAI-1 gene. The invention also relates to an inhibitor of PAI-1 for use in the treatment of PPCM. Also a method of treating PPCM in a subject in need of such a treatment, wherein said method comprises administering to said subject an effective amount of an inhibitor of PAI-1 is comprised in the present invention. Moreover, the present invention further relates to the use of a binding molecule for identifying a subject, which has PPCM or which has a risk for developing PPCM, wherein said binding molecule specifically binds to PAI-1.Type: GrantFiled: September 8, 2016Date of Patent: September 15, 2020Assignee: Medizinische Hochschule HannoverInventors: Denise Hilfiker-Kleiner, Justus Nonhoff
-
Publication number: 20200283848Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.Type: ApplicationFiled: October 9, 2018Publication date: September 10, 2020Applicants: MEDIZINISCHE HOCHSCHULE HANNOVER, TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, TECHNISCHE UNIVERSITÄT DRESDENInventors: Daniel TODT, Sibylle HAID, Martin WETZKE, Gesine HANSEN, Chris LAUBER, Lars KADERALI, Thomas PIETSCHMANN
-
Patent number: 10709816Abstract: The invention relates to implants that are implanted into living beings as temporary implants and that disintegrate in the body through biological adsorption over a period of time, in addition to a process for producing aforesaid implants. The implant according to the invention consists of magnesium or a magnesium master alloy. It is formed from fibers of magnesium or a magnesium master alloy that are connected to one another through sintering bridges that are locally spaced vis-à-vis each other and form an open-pored body. The fibers may be produced with the help of the melt extraction process and may subsequently be sintered with one another.Type: GrantFiled: July 27, 2011Date of Patent: July 14, 2020Assignees: Medizinische Hochschule Hannover (MHH), Fraunhofer-Gesekkschaft zur Foerderung der angewandten Forschung e.V.Inventors: Olaf Andersen, Ingrid Morgenthal, Thomas Studnitzky, Frank Witte
-
Patent number: 10668272Abstract: A cochlear implant of a cochlear implant system is described. The cochlear implant comprises electrodes which are mechanically connected to one another and can be inserted in a row in the form of a spiral into a cochlea in order for auditory nerve receptors to be stimulated, a control circuit that can specifically apply electric pulses to the individual electrodes, and an energy source. The control circuit allows the electrodes to be fed in a pulsed manner with electric signals generated by a processor from the acoustic signals, and auditory nerve receptors adjacent to the electrodes to be stimulated. The electrodes are components of modules, each of which comprises its own decoder-and-control circuit for decoding module addresses and stimulation signals and generating electric pulses for the electrodes. Encoded module addresses and stimulation signals generated from acoustic signals are applied to inputs of the decoder-and-control circuit.Type: GrantFiled: July 27, 2016Date of Patent: June 2, 2020Assignees: MEDIZINISCHE HOCHSCHULE HANNOVER, GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVERInventors: Holger Blume, Wolfgang Ertmer, Thomas Lenarz, Andrej Kral
-
Patent number: 10641780Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.Type: GrantFiled: March 15, 2018Date of Patent: May 5, 2020Assignees: The Governors of the University of Alberta, Medizinische Hochschule HannoverInventors: Abdolamir Landi, Michael Houghton, D. Lorne Tyrrell, Tim Lankisch, Tobias Weismueller, Michael Manns
-
Publication number: 20200093888Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.Type: ApplicationFiled: October 28, 2019Publication date: March 26, 2020Applicants: Helmholtz-Zentrum Für Infektionsforschung GMBH, Medizinische Hochschule Hannover, Twincore, Zentrum Für Experimentelle und Klinische Infektionsforschung GMBHInventors: Mark Brönstrup, Hans-Peter Prochnow, N.V. Suryanarayana Birudukota, Thomas Schulz, Martin Messerle, Thomas Pietschmann, Sibylle Haid, Sebastian Blockus, Christine Laqmani-Goffinet, Sergej Franz, Dominic Howard Banda
-
Patent number: 10584383Abstract: The present invention relates to a method for predicting mortality of a test patient with chronic heart failure comprising based on detecting the expression level of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 8. The present invention also relates to a method for predicting cardiac remodeling after myocardial infarction in a test patient based on detecting the expression level of one or more lncRNAs selected from SEQ ID NOs 1 to 8.Type: GrantFiled: March 18, 2015Date of Patent: March 10, 2020Assignees: MEDIZINISCHE HOCHSCHULE HANNOVER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ DE LILLE 2 (LILLE 2)—UNIVERSITY OF LAW AND HEALTH, CENTRE HOSPITALIER UNIVERSITAIRE LILLE (CHU), INSTITUT PASTEUR DE LILLE (IPL)Inventors: Thomas Thum, Regalla Kumarswamy, Florence Pinet, Christophe Bauters, Pascal De Groote
-
Patent number: 10500306Abstract: The tissue construct with viable cells in an extracellular matrix made of fibrin is produced with a special method, in which a matrix material and cells are shaped into a hollow body, in particular a tubular hollow body, by means of a rotational casting method in a hollow mould (1), the method comprising the following steps: (a) introduction of cells of at least one cell type and/or a fibrinogen preparation into the rotating hollow mould (1) with the aid of an applicator (4), said applicator (4) being displaced along the rotational axis during the introduction and step (a) being performed one or more times; (b) continuation of the rotation process until the fibrinogen solidifies into a dimensionally stable matrix, obtaining a primarily solidified tissue construct; (c) removal of the tissue construct from the mould. The construct can also he obtained in a relatively short time from autologous materials.Type: GrantFiled: December 20, 2012Date of Patent: December 10, 2019Assignee: MEDIZINISCHE HOCHSCHULE HANNOVERInventors: Thomas Aper, Mathias Wilhelmi, Axel Haverich
-
Patent number: 10441377Abstract: The invention is related to a surgical device for patient-specific guidance of at least one tool used during a surgical intervention, comprising at least the following features: a) at least one carrier system which is arranged for fixation on a bone structure of a patient, b) at least one guiding system connectable to the carrier system, the at least one guiding system comprising at least one base module and at least one guiding part for precisely defined guidance of at least one tool used during the surgical intervention, c) at least one connecting means for establishing a mechanical connection between the at least one guiding part and the at least one base module, wherein the connecting means comprises at least a non-fixed operating state and a fixed operating state, wherein in the non-fixed operating state the at least one guiding part can be adjusted relative to the base module in a patient-specific adjustment and in the fixed operating state the at least one guiding part is mechanically fixated relativeType: GrantFiled: February 9, 2016Date of Patent: October 15, 2019Assignee: Medizinische Hochschule HannoverInventors: Thomas Stephen Rau, Omid Majdani, Thomas Lenarz, Luder Alexander Kahrs
-
Patent number: 10407703Abstract: The present invention relates to in vitro methods for producing Neisseria meningitidis capsular polysaccharides which have a defined length. The present invention also relates to compositions comprising at least one capsule polymerase, at least one donor carbohydrate and at least one acceptor carbohydrate, wherein the ratio of donor carbohydrate to acceptor carbohydrate is a ratio from 10:1 to 400:1. Moreover, the present invention provides truncated versions of the capsule polymerases of Neisseria meningitidis serogroups A and X. Also provided herein are pharmaceuticals, in particular vaccines, comprising the synthetic capsular polysaccharides of Neisseria meningitidis which have a defined length. Furthermore, the invention provides for methods for the production of said vaccines.Type: GrantFiled: April 17, 2015Date of Patent: September 10, 2019Assignee: Medizinische Hochschule HannoverInventors: Timm Fiebig, Tim Keys, Friedrich Freiberger, Angela Romanow, Andrea Bethe, Monika Berger, Rita Gerardy-Schahn